Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with history of CAD or participants categorized in 'high risk' by Japan Atherosclerosis Society (JAS) 2017 guidelines or participants with heterozygous familial hypercholesterolemia (HeFH)~* As per the JAS 2017 guideline, participants not meeting the LDL-C management targets.~* Participants on statins should be receiving a maximally tolerated dose.~* Participants not receiving statins must have documented evidence of intolerance to at least one statin.~* The lipid-lowering therapy should have remained stable for ≥ 30 days before screening with no planned medication/ dose change until Day 180~Exclusion Criteria:~* Participants diagnosed with homozygous familial hypercholesterolemia (HoFH).~* Treatment (within 90 days of screening) with monoclonal antibodies directed towards PCSK9.~* New York Heart Association (NYHA) class IV heart failure or last known left ventricular ejection fraction \<25%.~* Cardiac arrhythmia within 3 months prior to randomization that is not controlled by medication or via ablation.~* Uncontrolled hypertension: systolic blood pressure \>160 mmHg or diastolic blood pressure \>100 mmHg prior to randomization despite antihypertensive therapy.~* Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained elevations in alanine aminotransferase (ALT), aspartate aminotransferase (AST), \>3x the upper limit of normal (ULN), or total bilirubin \>2x ULN at screening.~* Severe concomitant non-cardiovascular disease that carries the risk of reducing life expectancy to less than 2 years.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 300 mg inclisiran sodium (Type: EXPERIMENTAL): Subcutaneous injection
- 200 mg inclisiran sodium (Type: EXPERIMENTAL): Subcutaneous injection
- 100 mg inclisiran sodium (Type: EXPERIMENTAL): Subcutaneous injection
- Placebo (Type: PLACEBO_COMPARATOR): Subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).